M. J. Biopharm Profile
Key Indicators
- Authorised Capital ₹ 40.00 Cr
- Paid Up Capital ₹ 23.01 Cr
- Company Age 22 Year, 7 Months
- Last Filing with ROC 31 Mar 2023
- Open Charges ₹ 151.00 Cr
- Satisfied Charges ₹ 42.78 Cr
- Revenue Growth 15.73%
- Profit Growth 27.68%
- Ebitda 15.39%
- Net Worth 9.38%
- Total Assets 21.88%
About M. J. Biopharm
M. J. Biopharm Private Limited (MJBPL) is a leading Private Limited Indian Non-Government Company incorporated in India on 27 June 2002 and has a history of 22 years and seven months. Its registered office is in Pune, Maharashtra, India.
The Corporate was formerly known as Mj Biogen Private Limited. The Company is engaged in the Pharma Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2023. It's a company limited by shares with an authorized capital of Rs 40.00 Cr and a paid-up capital of Rs 23.01 Cr.
The company currently has active open charges totaling ₹151.00 Cr. The company has closed loans amounting to ₹42.78 Cr, as per Ministry of Corporate Affairs (MCA) records.
The Key Managerial Personnel (KMP) at M. J. Biopharm Private Limited India is Pradakshina Goswami as COMPANY SECRETARY. Amol Shah, Pheroze Mistry, Kajal Shah, and One other member serve as directors at the Company.
Company Details
- Location
Pune, Maharashtra, India
- Telephone
+91-XXXXXXXXXX
- Email Address
- Website
- Social Media
Corporate Identity Details
- CIN/LLPIN
U24234PN2002PTC158855
- Company No.
158855
- Company Classification
Private Limited Indian Non-Government Company
- Incorporation Date
27 Jun 2002
- Date of AGM
28 Aug 2023
- Date of Balance Sheet
31 Mar 2023
- Listing Status
Unlisted
- ROC Code
Roc Pune
Industry
What products or services does M. J. Biopharm Private Limited offer?
M. J. Biopharm Private Limited offers a wide range of products and services, including Cardiovascular Drugs & Medication, Diabetes Medicine.
Who are the key members and board of directors at M. J. Biopharm?
Executive Team (2)
Name | Designation | Appointment Date | Status |
---|---|---|---|
Amol Shah ![]() | Managing Director | 09-Nov-2010 | Current |
Pradakshina Goswami | Company Secretary | 08-May-2023 | Current |
Board Members (3)
Name | Designation | Appointment Date | Status |
---|---|---|---|
Kajal Shah ![]() | Director | 24-Mar-2022 | Current |
Dhaval Vashi ![]() | Director | 10-Dec-2012 | Current |
Pheroze Mistry ![]() | Nominee Director | 04-May-2018 | Current |
Financial Performance of M. J. Biopharm.
M. J. Biopharm Private Limited, for the financial year ended 2023, experienced significant growth in revenue, with a 15.73% increase. The company also saw a substantial improvement in profitability, with a 27.68% increase in profit. The company's net worth moved up by a moderate rise of 9.38%.


- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
Metrics |
| (FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
---|---|---|---|---|---|---|---|
Total Revenue |
| ||||||
Revenue from Operations |
| ||||||
Total Assets |
| ||||||
Profit or Loss |
| ||||||
Net Worth |
| ||||||
EBITDA |
|
What is the Ownership and Shareholding Structure of M. J. Biopharm?
In 2023, M. J. Biopharm had a promoter holding of 70.00% and a public holding of 30.00%. The company had 1 Subsidiary and 1 Associate company. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.

Charges (Loans)
₹151.00 Cr
₹42.78 Cr
Charges Breakdown by Lending Institutions
- Sbicap Trustee Company Limited : 151.00 Cr
Latest Charge Details
Date | Lender | Amount | Status |
---|---|---|---|
31 May 2022 | Sbicap Trustee Company Limited | ₹151.00 Cr | Open |
04 Dec 2015 | Others | ₹3.00 Cr | Satisfied |
17 Nov 2015 | Icici Bank Limited | ₹5.00 Cr | Satisfied |
09 Jan 2014 | Icici Bank Limited | ₹2.50 Cr | Satisfied |
20 Dec 2013 | Icici Bank Limited | ₹12.00 Cr | Satisfied |
How Many Employees Work at M. J. Biopharm?
M. J. Biopharm has a workforce of 315 employees as of Apr 10, 2024. Unlock access to detailed historical data on individuals associated with the company, including employment records, contributions to the Employees' Provident Fund Organization (EPFO), and other related insights.

Deals i

Gain comprehensive insights into the Deals and Valuation data of M. J. Biopharm, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped M. J. Biopharm's trajectory.
Rating

Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts

Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.